Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK39297 in PNH Patients with Anemia on Anti-C5 Therapy
NCT07052838Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ciprocopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Proportion of participants achieving hemoglobin levels ≥ 120 g/L. Started May 2025; status: completed.
02
Drugs
ciprocopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07052838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052838.